• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample

    ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    UK Brucellosis Market

    ID: MRFR/LS/51827-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    UK Brucellosis Market Research Report By species (Brucella suis, B. abortus, B. melitensis)-Forecast to 2035

    Share:

    Download PDF

    ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    UK Brucellosis Market Research Report- Forecast To 2035 Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    UK Brucellosis Market Summary

    The United Kingdom Brucellosis market is projected to experience substantial growth from 2024 to 2035.

    Key Market Trends & Highlights

    UK Brucellosis Key Trends and Highlights

    • The market valuation is expected to rise from 13.9 USD Million in 2024 to 62.5 USD Million by 2035.
    • A compound annual growth rate (CAGR) of 14.61 percent is anticipated for the period between 2025 and 2035.
    • The increasing prevalence of brucellosis in livestock is likely to drive market expansion in the UK.
    • Growing adoption of advanced diagnostic technologies due to heightened awareness of zoonotic diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 13.9 (USD Million)
    2035 Market Size 62.5 (USD Million)
    CAGR (2025-2035) 14.61%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Elanco, Intervet, Hipra, Neogen, MSD Animal Health, Vetoquinol, Heska, Merck Animal Health, Boehringer Ingelheim, Ceva Santé Animale, Virbac, Bimeda, Wockhardt, Lohmann Animal Health, Zoetis

    UK Brucellosis Market Trends

    Currently, a number of important market trends are influencing the UK brucellosis industry. The growing concerns about food safety and animal health, which have prompted more monitoring and brucellosis immunization programs for livestock, are among the major factors propelling the market.

    In order to preserve the integrity of the agricultural industry, the UK government aggressively supports biosecurity measures that stop the introduction and spread of brucellosis in sheep and cattle.

    In order to guarantee a coordinated response to outbreaks and present a unified front against the disease, cooperation between veterinary authorities, farmers, and agricultural groups is also growing increasingly frequent. Additionally, there are noteworthy prospects in the UK brucellosis market.

    There is an opportunity to improve illness identification and treatment by focusing on research and development for efficient vaccinations and diagnostics. Additionally, farmers are encouraged to use healthier livestock management practices by the growing interest in sustainable farming methods, which can help lower the prevalence of brucellosis.

    Recent trends show that the public is becoming more aware of zoonotic illnesses, which has led to increased brucellosis education initiatives. Governmental organizations that describe the dangers of eating unpasteurized dairy products provide support to this.

    There is a drive to certify brucellosis-free products in order to bring value to the market, as consumers' preferences for openness in food supply grow. All things considered, the UK brucellosis market is changing as a result of continuous initiatives to reduce hazards and improve animal health, setting up the industry for expansion and improved human and animal health outcomes.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    UK Brucellosis Market Drivers

    Market Segment Insights

    Brucellosis Market species Insights

    Brucellosis Market species Insights

    The UK Brucellosis Market focuses on various species contributing to the overall landscape, primarily encompassing Brucella suis, B. abortus, and B. melitensis, which are critical in the study and management of this infectious disease in animals and humans.

    Brucella suis is significant as it affects swine populations, making it essential for livestock industries to manage this zoonotic disease effectively, as it poses a risk for transmission to humans. B. abortus, typically associated with cattle, dominates the market due to its impact on agricultural operations, where outbreaks can lead to significant financial losses and regulatory challenges.

    The importance of this species cannot be overstated; in the UK, cattle are cornerstone assets in the agricultural ecosystem, and controlling B. abortus is paramount in ensuring both health and economic stability in the sector.

    Conversely, B. melitensis, primarily linked with goats and sheep, presents its own challenges due to its capability to cause severe human infections, thus affecting public health initiatives. The vigilance and resource allocation towards monitoring and controlling these species are reflected in the demand for diagnostic tools and vaccines.

    Get more detailed insights about UK Brucellosis Market Research Report- Forecast To 2035

    Regional Insights

    Key Players and Competitive Insights

    The competitive landscape of the UK Brucellosis Market is characterized by a growing emphasis on animal health, biosecurity measures, and innovative pharmaceutical solutions tailored to address the challenges posed by Brucellosis. This zoonotic disease affects livestock, primarily cattle, goats, and sheep, leading to economic losses for farmers and posing public health risks.

    The market consists of various players, including global pharmaceutical companies and specialized veterinary service providers, each vying to establish a foothold through strategic partnerships, research and development initiatives, and marketing efforts aimed at educating stakeholders about disease prevention and management.

    As the awareness of Brucellosis's implications on livestock and public health intensifies, the competition among market players is expected to lead to the introduction of advanced diagnostic tools and vaccines, as well as more effective treatment options, enhancing overall market growth.

    Elanco holds a prominent position in the UK Brucellosis Market, leveraging its extensive portfolio of animal health products and solutions aimed at preventing and controlling infectious diseases. The company is recognized for its commitment to research and development, which enables Elanco to provide effective vaccines and diagnostic tools for Brucellosis.

    Its strength lies in its established relationships with veterinary professionals and livestock producers, allowing for seamless product integration into existing animal health management practices. Furthermore, Elanco's active engagement in educational initiatives contributes to improved awareness and understanding of Brucellosis, thereby strengthening its market presence.

    The ability to offer comprehensive support and service provisions to livestock producers sets Elanco apart from its competitors, establishing it as a leader in the UK market.

    Intervet, a key player in the UK Brucellosis Market, is known for its robust portfolio of veterinary vaccines and pharmaceutical products tailored specifically for the prevention and treatment of Brucellosis in livestock.

    With a strong focus on innovation, Intervet continuously invests in research and development to enhance its offerings, ensuring they meet the evolving needs of the agriculture sector. Their extensive market presence is supported by a strategic approach that includes partnerships with veterinary practices and agricultural organizations, reinforcing their commitment to animal health and biosecurity measures.

    Intervet's strength lies in its ability to create tailored solutions that address the specific challenges faced by farmers in the UK. This is further underscored by their active engagement in collaborations and potential mergers that expand their reach and enhance their competitive edge within the Brucellosis Market.

    The company's comprehensive offerings enable them to cater to a wide range of livestock health needs, positioning them as a vital contributor to the ongoing combat against Brucellosis in the UK.

    Key Companies in the UK Brucellosis Market market include

    Industry Developments

    The UK Brucellosis Market has seen several notable developments recently, particularly in the ongoing efforts to control the disease among livestock, enhancing the demand for effective diagnostics and vaccines. Companies such as Elanco and Merck Animal Health have been actively involved in Research and Development initiatives aimed at improving their product offerings for Brucellosis management.

    Furthermore, market growth has been observed, attributed to increased awareness and regulations concerning animal health; the market is projected to grow significantly in the coming years, contributing to the economic stability of the livestock sector.

    Notably, in October 2022, Intervet announced the acquisition of key assets from a smaller competitor, strengthening its position in the Brucellosis vaccine segment. Additionally, Boehringer Ingelheim has expanded its facility in the UK devoted to producing vaccines, underscoring a commitment to addressing livestock disease challenges.

    The UK government has also allocated funds for disease management, incentivizing innovation and research to combat Brucellosis effectively. Overall, the convergence of regulatory support, company expansions, and technological advancements is shaping a dynamic landscape in the UK Brucellosis Market.

    Market Segmentation

    Brucellosis Market species Outlook

    • Brucella suis
    • B. abortus
    • B. melitensis

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2023 12.81(USD Million)
    MARKET SIZE 2024 13.95(USD Million)
    MARKET SIZE 2035 62.5(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 14.607% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED Elanco, Intervet, Hipra, Neogen, MSD Animal Health, Vetoquinol, Heska, Merck Animal Health, Boehringer Ingelheim, Ceva Santé Animale, Virbac, Bimeda, Wockhardt, Lohmann Animal Health, Zoetis
    SEGMENTS COVERED species
    KEY MARKET OPPORTUNITIES Increasing awareness programs, Enhanced diagnostic technologies, Innovative vaccine development, Government funding initiatives, Growing livestock healthcare demand
    KEY MARKET DYNAMICS increasing livestock disease awareness, government regulations on animal health, advancements in diagnostic technologies, rising zoonotic disease concerns, collaboration among veterinary professionals
    COUNTRIES COVERED UK

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the expected market size of the UK Brucellosis Market in 2024?

    The UK Brucellosis Market is expected to be valued at 13.95 million USD in 2024.

    What will the market value of the UK Brucellosis Market be in 2035?

    In 2035, the UK Brucellosis Market is projected to be valued at 62.5 million USD.

    What is the expected CAGR for the UK Brucellosis Market from 2025 to 2035?

    The expected CAGR for the UK Brucellosis Market during the forecast period is 14.607%.

    Which species segments are included in the UK Brucellosis Market?

    The market is segmented into Brucella suis, B. abortus, and B. melitensis.

    What is the market value for Brucella suis in 2024?

    Brucella suis is expected to be valued at 5.0 million USD in 2024.

    What is the projected market size for B. abortus in 2035?

    B. abortus is anticipated to reach a market value of 22.0 million USD by 2035.

    Who are the key players in the UK Brucellosis Market?

    Major players in the market include Elanco, Intervet, Hipra, Neogen, and MSD Animal Health.

    What is the estimated market size for B. melitensis in 2024?

    The market value for B. melitensis in 2024 is estimated to be 4.0 million USD.

    What growth drivers are influencing the UK Brucellosis Market?

    Increased awareness and demand for animal health products are key growth drivers.

    What challenges might affect the growth of the UK Brucellosis Market?

    Regulatory hurdles and market competition can pose significant challenges for growth.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. UK Brucellosis Market, BY species (USD Million)
    45. Brucella suis
    46. B. abortus
    47. B. melitensis
    48. Competitive Landscape
    49. Overview
    50. Competitive Analysis
    51. Market share Analysis
    52. Major Growth Strategy in the Brucellosis Market
    53. Competitive Benchmarking
    54. Leading Players in Terms of Number of Developments in the Brucellosis Market
    55. Key developments and growth strategies
    56. New Product Launch/Service Deployment
    57. Merger & Acquisitions
    58. Joint Ventures
    59. Major Players Financial Matrix
    60. Sales and Operating Income
    61. Major Players R&D Expenditure. 2023
    62. Company Profiles
    63. Elanco
    64. Financial Overview
    65. Products Offered
    66. Key Developments
    67. SWOT Analysis
    68. Key Strategies
    69. Intervet
    70. Financial Overview
    71. Products Offered
    72. Key Developments
    73. SWOT Analysis
    74. Key Strategies
    75. Hipra
    76. Financial Overview
    77. Products Offered
    78. Key Developments
    79. SWOT Analysis
    80. Key Strategies
    81. Neogen
    82. Financial Overview
    83. Products Offered
    84. Key Developments
    85. SWOT Analysis
    86. Key Strategies
    87. MSD Animal Health
    88. Financial Overview
    89. Products Offered
    90. Key Developments
    91. SWOT Analysis
    92. Key Strategies
    93. Vetoquinol
    94. Financial Overview
    95. Products Offered
    96. Key Developments
    97. SWOT Analysis
    98. Key Strategies
    99. Heska
    100. Financial Overview
    101. Products Offered
    102. Key Developments
    103. SWOT Analysis
    104. Key Strategies
    105. Merck Animal Health
    106. Financial Overview
    107. Products Offered
    108. Key Developments
    109. SWOT Analysis
    110. Key Strategies
    111. Boehringer Ingelheim
    112. Financial Overview
    113. Products Offered
    114. Key Developments
    115. SWOT Analysis
    116. Key Strategies
    117. Ceva Santé Animale
    118. Financial Overview
    119. Products Offered
    120. Key Developments
    121. SWOT Analysis
    122. Key Strategies
    123. Virbac
    124. Financial Overview
    125. Products Offered
    126. Key Developments
    127. SWOT Analysis
    128. Key Strategies
    129. Bimeda
    130. Financial Overview
    131. Products Offered
    132. Key Developments
    133. SWOT Analysis
    134. Key Strategies
    135. Wockhardt
    136. Financial Overview
    137. Products Offered
    138. Key Developments
    139. SWOT Analysis
    140. Key Strategies
    141. Lohmann Animal Health
    142. Financial Overview
    143. Products Offered
    144. Key Developments
    145. SWOT Analysis
    146. Key Strategies
    147. Zoetis
    148. Financial Overview
    149. Products Offered
    150. Key Developments
    151. SWOT Analysis
    152. Key Strategies
    153. References
    154. Related Reports
    155. LIST OF ASSUMPTIONS
    156. UK Brucellosis Market SIZE ESTIMATES & FORECAST, BY SPECIES, 2019-2035 (USD Billions)
    157. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    158. ACQUISITION/PARTNERSHIP
    159.                                                           LIST Of figures  
    160. MARKET SYNOPSIS
    161. UK BRUCELLOSIS MARKET ANALYSIS BY SPECIES
    162. KEY BUYING CRITERIA OF BRUCELLOSIS MARKET
    163. RESEARCH PROCESS OF MRFR
    164. DRO ANALYSIS OF BRUCELLOSIS MARKET
    165. DRIVERS IMPACT ANALYSIS: BRUCELLOSIS MARKET
    166. RESTRAINTS IMPACT ANALYSIS: BRUCELLOSIS MARKET
    167. SUPPLY / VALUE CHAIN: BRUCELLOSIS MARKET
    168. BRUCELLOSIS MARKET, BY SPECIES, 2025 (% SHARE)
    169. BRUCELLOSIS MARKET, BY SPECIES, 2019 TO 2035 (USD Billions)
    170. BENCHMARKING OF MAJOR COMPETITORS

    UK Brucellosis Market Segmentation

    • Brucellosis Market By species (USD Million, 2019-2035)

      • Brucella suis
      • B. abortus
      • B. melitensis
    Report Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study

    Chemicals and Materials